Recently, the FDA has approved tazemetostat, the first inhibitor of EZH2 (a top core regulator in GII), for treating epithelioid sarcoma, indicating EZH2 as a potential target in LUAD [65]. The gene discussed is EZH2; the disease is epithelioid sarcoma.